$SHPH
Shuttle Pharmaceuticals Holdings, Inc. Stock $shph

$shph Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-Q Financial Statement

#000149315224018944 Filed on May 13, 2024

Income Statement

Concept	2024 Q2	2024 Q1	2023 Q1
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin			$534.0K
YoY Change			55.91%
% of Gross Profit
Research & Development	$645.7K	$586.1K	$1.011M
YoY Change	-30.82%	-42.02%	241.58%
% of Gross Profit
Depreciation & Amortization		$1.912K	$1.488K
YoY Change		28.49%	2.62%
% of Gross Profit
Operating Expenses	$1.483M	$1.385M	$1.545M
YoY Change	1.16%	-10.35%	141.98%
Operating Profit	-$1.483M	-$1.385M	-$1.545M
YoY Change	1.16%	-10.35%	141.98%
Interest Expense			$692.2K
YoY Change			-694.4%
% of Operating Profit
Other Income/Expense, Net	-$548.6K	-$346.2K	$569.7K
YoY Change	-23.67%	-160.77%	-1411.33%
Pretax Income			-$975.1K
YoY Change			43.01%
Income Tax
% Of Pretax Income
Net Earnings	-$2.031M	-$1.700M	-$975.1K
YoY Change	-7.01%	74.34%	43.01%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.96	-$0.10	-$0.07
Diluted Earnings Per Share	-$0.96	-$0.10	-$0.07
COMMON SHARES
Basic Shares Outstanding	16.79M shares	16.79M shares	13.65M shares
Diluted Shares Outstanding	2.105M shares	16.57M shares	13.64M shares

Balance Sheet

Concept	2024 Q2	2024 Q1	2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments			$10.16M
YoY Change			49196.46%
Cash & Equivalents	$695.6K	$1.399M	$7.169M
Short-Term Investments			$2.990M
Other Short-Term Assets		$81.53K	$200.0K
YoY Change		-59.23%	-50.72%
Inventory
Prepaid Expenses	$139.5K	$129.6K	$203.8K
Receivables			$10.00K
Other Receivables			$0.00
Total Short-Term Assets	$2.485M	$4.411M	$10.37M
YoY Change	-70.56%	-57.47%	2332.03%
LONG-TERM ASSETS
Property, Plant & Equipment	$21.95K	$22.92K	$11.10K
YoY Change	128.15%	106.37%	-90.71%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets			$10.00K
YoY Change			54.32%
Total Long-Term Assets	$327.7K	$342.9K	$64.62K
YoY Change	-16.79%	430.68%	-48.71%
TOTAL ASSETS
Total Short-Term Assets	$2.485M	$4.411M	$10.37M
Total Long-Term Assets	$327.7K	$342.9K	$64.62K
Total Assets	$2.813M	$4.754M	$10.44M
YoY Change	-68.17%	-54.45%	1789.13%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable			$450.0K
YoY Change			-34.9%
Accrued Expenses			$180.0K
YoY Change			25.67%
Deferred Revenue
YoY Change
Short-Term Debt			$140.0K
YoY Change			-87.41%
Long-Term Debt Due			$620.0K
YoY Change
Total Short-Term Liabilities	$1.385M	$1.489M	$1.388M
YoY Change	180.47%	7.26%	-41.12%
LONG-TERM LIABILITIES
Long-Term Debt			$750.0K
YoY Change
Other Long-Term Liabilities			$1.390M
YoY Change			3041.24%
Total Long-Term Liabilities			$2.140M
YoY Change			4736.16%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.385M	$1.489M	$1.388M
Total Long-Term Liabilities			$2.140M
Total Liabilities	$2.012M	$1.992M	$3.530M
YoY Change	5.79%	-43.56%	46.96%
SHAREHOLDERS EQUITY
Retained Earnings	-$29.20M	-$17.22M	-$9.870M
YoY Change	142.2%	74.45%
Common Stock	$21.00	$168.00	$137.00
YoY Change	-86.45%	22.63%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$801.4K	$2.761M	$6.906M
YoY Change
Total Liabilities & Shareholders Equity	$2.813M	$4.754M	$10.44M
YoY Change	-68.17%	-54.45%	1789.13%

Cashflow Statement

Concept	2024 Q2	2024 Q1	2023 Q1
OPERATING ACTIVITIES
Net Income	-$2.031M	-$1.700M	-$975.1K
YoY Change	-7.01%	74.34%	43.01%
Depreciation, Depletion And Amortization		$1.912K	$1.488K
YoY Change		28.49%	2.62%
Cash From Operating Activities		-$1.239M	-$1.338M
YoY Change		-7.39%	114.21%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities			-$2.954M
YoY Change
Cash From Investing Activities		$101.3K	-$2.954M
YoY Change		-103.43%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		-$40.00K	$3.044M
YoY Change		-101.31%	478.97%
NET CHANGE
Cash From Operating Activities		-$1.239M	-$1.338M
Cash From Investing Activities		$101.3K	-$2.954M
Cash From Financing Activities		-$40.00K	$3.044M
Net Change In Cash		-$1.178M	-$1.248M
YoY Change		-5.62%	1161.94%
FREE CASH FLOW
Cash From Operating Activities		-$1.239M	-$1.338M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent		usd
CY2023Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent		usd
CY2024Q1	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable		usd
CY2024Q1	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2024Q1	us-gaap	Revenues Revenues		usd
CY2024Q1	SHPH	Finance Fee FinanceFee		usd
CY2023Q1	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments		usd
CY2024Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross		usd
CY2023Q1	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments		usd
CY2024Q1	SHPH	Increase Decrease In Accrued Interest Payable Related Parties IncreaseDecreaseInAccruedInterestPayableRelatedParties		usd
CY2024Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets		usd
CY2023Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities		usd
CY2024Q1	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt		usd
CY2024Q1	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt		usd
CY2024Q1	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts		usd
CY2023Q1	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts		usd
CY2024Q1	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2024Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2023Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2023Q1	SHPH	Finance Costs Accrued In Accounts Payable FinanceCostsAccruedInAccountsPayable		usd
CY2024Q1	SHPH	Warrants Issued For Financing Fees WarrantsIssuedForFinancingFees		usd
CY2024Q1	us-gaap	Revenues Revenues		usd
CY2024Q1	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure		usd
CY2023Q1	us-gaap	Variable Lease Cost VariableLeaseCost		usd
CY2024Q1	us-gaap	Other Assets Current OtherAssetsCurrent	81534	usd
CY2024Q1	us-gaap	Assets Current AssetsCurrent	4411019	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	22915	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	319987	usd
CY2024Q1	us-gaap	Assets Assets	4753921	usd
CY2024Q1	us-gaap	Interest Payable Current InterestPayableCurrent	143676	usd
CY2023Q4	us-gaap	Interest Payable Current InterestPayableCurrent	110453	usd
CY2024Q1	SHPH	Convertible Note Payable Current ConvertibleNotePayableCurrent	941398	usd
CY2023Q4	SHPH	Convertible Note Payable Current ConvertibleNotePayableCurrent	595999	usd
CY2024Q1	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	2035	usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	54552	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	52479	usd
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	1489217	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1042237	usd
CY2023Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	135089	usd
CY2024Q1	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	214615	usd
CY2023Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	414512	usd
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	288602	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	304127	usd
CY2024Q1	us-gaap	Liabilities Liabilities	1992434	usd
CY2023Q4	us-gaap	Liabilities Liabilities	1895965	usd
CY2024Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2024Q1	us-gaap	Preferred Stock Liquidation Preference PreferredStockLiquidationPreference	1000
CY2023Q4	us-gaap	Preferred Stock Liquidation Preference PreferredStockLiquidationPreference	1000
CY2024Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2024Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	16819893	shares
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	16819893	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	16069320	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	16069320	shares
CY2024Q1	us-gaap	Common Stock Value CommonStockValue	168	usd
CY2024Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	19979962	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-17218643	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	2761487	usd
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	4753921	usd
CY2024Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	586104	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	921801	usd
CY2024Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	324609	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	255355	usd
CY2024Q1	us-gaap	Legal Fees LegalFees	474134	usd
CY2023Q1	us-gaap	Legal Fees LegalFees	367624	usd
CY2024Q1	us-gaap	Operating Expenses OperatingExpenses	1384847	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	1544780	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-1384847	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-1544780	usd
CY2024Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	21453	usd
CY2023Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	16688	usd
CY2023Q1	SHPH	Finance Fee FinanceFee	104245	usd
CY2024Q1	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	197862	usd
CY2023Q1	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	1241000	usd
CY2024Q1	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	4037	usd
CY2024Q1	us-gaap	Marketable Securities Gain Loss Excluding Other Than Temporary Impairments MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments	-706	usd
CY2023Q1	us-gaap	Marketable Securities Gain Loss Excluding Other Than Temporary Impairments MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments	38062	usd
CY2024Q1	SHPH	Loss On Settlement Of Convertible Debt LossOnSettlementOfConvertibleDebt	71315	usd
CY2023Q1	SHPH	Loss On Settlement Of Convertible Debt LossOnSettlementOfConvertibleDebt	18254	usd
CY2024Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-346184	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	569683	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-1731031	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-975097	usd
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	16572527	shares
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	16572527	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	13635994	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	13635994	shares
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.10
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.10
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.07
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.07
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	4055771	usd
CY2024Q1	SHPH	Stock Issued During Period Value Conversion Of Accrued Interest And Principal StockIssuedDuringPeriodValueConversionOfAccruedInterestAndPrincipal	325298	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	111449	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-1731031	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	2761487	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	7677869	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	7677869	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	99543	usd
CY2023Q1	SHPH	Adjustments To Additional Paid In Capital Financing Fees Allocated To Warrants AdjustmentsToAdditionalPaidInCapitalFinancingFeesAllocatedToWarrants	-8727	usd
CY2023Q1	SHPH	Stock Issued During Period Value Conversion Of Accrued Interest And Principal StockIssuedDuringPeriodValueConversionOfAccruedInterestAndPrincipal	104547	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	8333	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-975097	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	6906468	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	6906468	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-1731031	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-975097	usd
CY2024Q1	us-gaap	Depreciation Depreciation	1912	usd
CY2023Q1	us-gaap	Depreciation Depreciation	1488	usd
CY2024Q1	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	197862	usd
CY2023Q1	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	1241000	usd
CY2024Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	445509	usd
CY2023Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	567297	usd
CY2024Q1	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	4037	usd
CY2024Q1	us-gaap	Marketable Securities Gain Loss Excluding Other Than Temporary Impairments MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments	-706	usd
CY2023Q1	us-gaap	Marketable Securities Gain Loss Excluding Other Than Temporary Impairments MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments	38062	usd
CY2024Q1	SHPH	Accrued Interest Settled With Common Stock AccruedInterestSettledWithCommonStock	18783	usd
CY2023Q1	SHPH	Accrued Interest Settled With Common Stock AccruedInterestSettledWithCommonStock	20142	usd
CY2024Q1	SHPH	Loss On Settlement Of Convertible Debt LossOnSettlementOfConvertibleDebt	71315	usd
CY2023Q1	SHPH	Loss On Settlement Of Convertible Debt LossOnSettlementOfConvertibleDebt	18254	usd
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	111449	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	8333	usd
CY2024Q1	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet	-2937	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet	7023	usd
CY2024Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	15169	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	42687	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	23162	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	330729	usd
CY2024Q1	us-gaap	Increase Decrease In Due To Related Parties Current IncreaseDecreaseInDueToRelatedPartiesCurrent	-446	usd
CY2023Q1	us-gaap	Increase Decrease In Due To Related Parties Current IncreaseDecreaseInDueToRelatedPartiesCurrent	-12500	usd
CY2024Q1	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	33223	usd
CY2023Q1	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	116051	usd
CY2023Q1	SHPH	Increase Decrease In Accrued Interest Payable Related Parties IncreaseDecreaseInAccruedInterestPayableRelatedParties	-74807	usd
CY2023Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	7206	usd
CY2024Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	466	usd
CY2023Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-1894	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1239083	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1337982	usd
CY2024Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	18705	usd
CY2023Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	2953709	usd
CY2024Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	120000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	101295	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2953709	usd
CY2023Q1	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	546244	usd
CY2023Q1	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	3935000	usd
CY2023Q1	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	345000	usd
CY2024Q1	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	40000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-40000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3043756	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1177788	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1247935	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	2576416	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	8417203	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1398628	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	7169268	usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet	79044	usd
CY2024Q1	SHPH	Common Stock Issued For Settlement Of Debt CommonStockIssuedForSettlementOfDebt	325298	usd
CY2023Q1	SHPH	Common Stock Issued For Settlement Of Debt CommonStockIssuedForSettlementOfDebt	104547	usd
CY2024Q1	SHPH	Finance Costs Accrued In Accounts Payable FinanceCostsAccruedInAccountsPayable	41534	usd
CY2024Q1	SHPH	Warrants Issuance Fees WarrantsIssuanceFees	0	usd
CY2023Q1	SHPH	Warrants Issuance Fees WarrantsIssuanceFees	8727	usd
CY2023Q1	SHPH	Warrants Issued For Financing Fees WarrantsIssuedForFinancingFees	90816	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-1700000	usd
CY2024Q1	SHPH	Working Capital WorkingCapital	2900000	usd
CY2022Q3	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	10000000.0	usd
CY2023Q1	us-gaap	Partners Capital PartnersCapital	4500000	usd
CY2023Q1	us-gaap	Prior Period Reclassification Adjustment PriorPeriodReclassificationAdjustment	89007	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	921801	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	255355	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	1177156	usd
CY2024Q1	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84A_eus-gaap--UseOfEstimates_z8w10KKZjfrg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_862_z8z4vAOOIrec">Use of Estimates</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions. The Company bases its estimates and assumptions on current facts, historical experience, and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected. Significant estimates are contained in the accompanying condensed consolidated financial statements for the valuation of derivatives, share-based compensation, and initial measurement of equity-based warrants.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q1	us-gaap	Cash Cash	364069	usd
CY2023Q4	us-gaap	Cash Cash	1550098	usd
CY2024Q1	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	1034559	usd
CY2023Q4	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	1026318	usd
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1398628	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2576416	usd
CY2024Q1	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2024Q1	us-gaap	Cash Uninsured Amount CashUninsuredAmount	1100000	usd
CY2024Q1	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	2789251	usd
CY2023Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	2887215	usd
CY2024Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	13651	usd
CY2023Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	16688	usd
CY2024Q1	us-gaap	Marketable Securities Realized Gain Loss Excluding Other Than Temporary Impairments MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments	4037	usd
CY2023Q1	us-gaap	Marketable Securities Realized Gain Loss Excluding Other Than Temporary Impairments MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments	0	usd
CY2024Q1	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	706	usd
CY2023Q1	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	38062	usd
CY2024Q1	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	2789251	usd
CY2023Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	2887215	usd
CY2023Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	414512	usd
CY2024Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2578438	shares
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3363007	shares
CY2023Q1	us-gaap	Operating Lease Payments Use OperatingLeasePaymentsUse	6480	usd
CY2023Q1	us-gaap	Lease Expiration Date1 LeaseExpirationDate1	2023-10-31
CY2024Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	22947	usd
CY2023Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	17544	usd
CY2024Q1	us-gaap	Variable Lease Cost VariableLeaseCost	10440	usd
CY2024Q1	us-gaap	Sublease Income SubleaseIncome	2163	usd
CY2023Q1	us-gaap	Sublease Income SubleaseIncome	2121	usd
CY2024Q1	us-gaap	Lease Cost LeaseCost	31224	usd
CY2023Q1	us-gaap	Lease Cost LeaseCost	15423	usd
CY2024Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	22482	usd
CY2023Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	19440	usd
CY2024Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y5M1D
CY2023Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P0Y6M21D
CY2024Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.1048	pure
CY2023Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.10	pure
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	69020	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	94246	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	97074	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	99986	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	68235	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	428561	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	85407	usd
CY2024Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	343154	usd
CY2024Q1	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	10000000	usd
CY2024Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	445509	usd
CY2023Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	463052	usd
CY2024Q1	us-gaap	Convertible Debt ConvertibleDebt	2019656	usd
CY2024Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1078258	usd
CY2024Q1	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	941398	usd
CY2024Q1	us-gaap	Stock Issued During Period Shares Conversion Of Convertible Securities StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities	625573	shares
CY2023Q1	us-gaap	Stock Issued During Period Shares Conversion Of Convertible Securities StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities	50998	shares
CY2023Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	1018079	shares
CY2023Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	2.35
CY2024Q1	SHPH	Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue	0	usd
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	605325	shares
CY2024Q1	us-gaap	Sale Of Stock Consideration Received Per Transaction SaleOfStockConsiderationReceivedPerTransaction	2250000	usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Description ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription	(i) one share of the Company’s common stock, (ii) a warrant to purchase one share of the Company’s common stock exercisable at a purchase price of $2.35 per share, and (iii) a percentage of equity interest in Diagnostics such that, assuming the sale of all $2,250,000 of Units, SRO LLC will own a 22% interest in Diagnostics
CY2024Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	4500000	usd
CY2024Q1	us-gaap	Sale Of Stock Consideration Received Per Transaction SaleOfStockConsiderationReceivedPerTransaction	2250000	usd
CY2024Q1	us-gaap	Direct Operating Costs DirectOperatingCosts	82000	usd
CY2023Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	1018079	shares
CY2023Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	2.35
CY2023Q1	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	1189000	usd
CY2024Q1	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	214615	usd
CY2023Q1	us-gaap	Derivative Fair Value Of Derivative Net DerivativeFairValueOfDerivativeNet	2631000	usd
CY2024Q1	us-gaap	Derivative Fair Value Of Derivative Net DerivativeFairValueOfDerivativeNet	216650	usd
CY2024Q1	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	0	usd
CY2023Q1	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	300000	usd

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
shph-20240331_cal.xml	Edgar Link	unprocessable
0001493152-24-018944-index-headers.html	Edgar Link	pending
0001493152-24-018944-index.html	Edgar Link	pending
0001493152-24-018944.txt	Edgar Link	pending
0001493152-24-018944-xbrl.zip	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
form10-q_htm.xml	Edgar Link	completed
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
shph-20240331.xsd	Edgar Link	pending
shph-20240331_def.xml	Edgar Link	unprocessable
shph-20240331_lab.xml	Edgar Link	unprocessable
shph-20240331_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SHPH
Shuttle Pharmaceuticals Holdings, Inc. Stock $shph

2024 Q2 Form 10-Q Financial Statement

#000149315224018944 Filed on May 13, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SHPH Shuttle Pharmaceuticals Holdings, Inc. Stock $shph

2024 Q2 Form 10-Q Financial Statement

#000149315224018944 Filed on May 13, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SHPH
Shuttle Pharmaceuticals Holdings, Inc. Stock $shph